Hannah Williams

Hannah Williams

Auto-generated profile, based on publicly available information

Hannah Williams

Center for Injury Research and Policy, Abigail Wexner Research Institute, Nationwide Children's Hospital, 700 Children's Drive, RB3, Columbus, OH, 43205, United States, 1 614-355-5890

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
LSLindsay M Sullivan
Lindsay M Sullivan
HVHarrison Vriese
Harrison Vriese
EFEllie Ferguson
Ellie Ferguson
MAMegan Armstrong
Megan Armstrong
HWHannah Williams
Hannah Williams
HXHenry Xiang
Henry Xiang
Background: Virtual reality (VR) technology holds significant potential for chronic pain management in children and adolescents by providing an alternative and complementary approach to traditional methods of alleviating pain and improving quality of life. Parents play an important role in the successful adoption of VR technologies for children, influencing how children accept, use, and benefit from it. However, little is known about parents’ views on integrating VR technology into pediatric and adolescent chronic pain management. Objective: This study aimed to better our understanding of parents’ perspectives regarding the integration of VR technology into pediatric and adolescent chronic pain management—including barriers, facilitators, and recommendations for future VR technologies. Methods: Semistructured interviews were conducted with parents of children with chronic pain between March and November 2024. Key aspects of the discussion centered on the acceptability, barriers, and enablers of integrating VR technology into pediatric and adolescent chronic pain management. Interviews were audio-recorded, transcribed, and analyzed through inductive thematic analysis. Results: We conducted 12 interviews. We identified four broad themes from the interview data: (1) views toward integrating VR technology into chronic pain management (perceived benefits, distraction, and redirection); (2) barriers to using VR technology for chronic pain management (accessibility, complexity, discomfort, and symptom exacerbation); (3) facilitators of integrating VR technology into chronic pain management (addressing financial barriers, integrating VR technology into clinical care, establishing evidence of effectiveness and showcasing positive patient experiences); and (4) recommendations for program content and features (relaxation and mindfulness, physical activity, customization, and social connection). Conclusions: Our findings underscore the perceived benefits of integrating VR technology into pediatric and adolescent chronic pain management to enhance physical, social, and mental health and well-being. However, there are several potential challenges that need to be addressed to improve the accessibility of VR technology for use in pediatric and adolescent chronic pain management. Our findings yielded several practical suggestions to guide the development of effective and equitable VR technology for chronic pain management in children and adolescents.

22 April 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MAMegan Armstrong
Megan Armstrong
HWHannah Williams
Hannah Williams
EFEsteban Fernandez Faith
Esteban Fernandez Faith
ANAi Ni
Ai Ni
HXHenry Xiang
Henry Xiang
Background: Lasers have wide applications in medicine and dermatology, but are associated with pain and anxiety, particularly in younger patients. Pain mitigation is often limited to topical anesthetics in the outpatient setting. Distraction techniques are limited by the need for ocular protection, which can include adhesive eye patches that can completely occlude vision. Virtual reality is effective at managing procedural pain and anxiety under other short medical procedures and is a promising tool for this population. Objective: This trial aims to assess the safety, feasibility, and efficacy of Virtual Reality Pain Alleviation Therapeutic (VR-PAT) for pain management during outpatient laser procedures. Methods: 40 patients requiring outpatient laser therapy for at least two sessions will be recruited from a pediatric hospital in the midwestern United States for this crossover randomized, two-arm clinical trial with a 1:1 allocation ratio. During the first laser visit, the participant will be randomly assigned to either play the VR-PAT game during their procedure or wear the headset with a dark screen. Participants will answer questions about their pain (Numeric Rating Scale (NRS) 0-10), anxiety (State Trait Anxiety Inventory for Children, NRS 0-10, Modified Yale Preoperative Anxiety Scale (mYPAS)), and pain medication usage. Those playing the VR-PAT will additionally report simulator sickness symptoms and their experience playing the game. At their second laser visit, participants will crossover to the opposite intervention from their first visit. The primary outcomes are the difference in self-reported pain and anxiety between the two interventions. Feasibility outcomes include the proportion of screened patients who are eligible, consent, and complete both visits and adverse events reported. To evaluate the efficacy of pain reduction, composite scores of pain score, pain medication will be calculated for each laser visit. To evaluate the efficacy of anxiety reduction, the change of mYPAS scores will be compared between control and VR groups at each visit using Wilcoxon rank sum tests. All statistical analyses will follow the intention-to-treat principle in regard to intervention assignment at each visit. Results: The study was funded in January 2023 and began enrollment at that time. A total of n=44 participants were recruited and data collection was completed in November 2025, with n=40 subjects completing both visits. The sample was balanced with n=40 subjects using the intervention and participating in the control condition. The age range of the complete sample was 6 to 21 years at recruitment and was 55% female sex. Data analysis is in progress with final results planned for June 2026. Conclusions: Findings from this innovative randomized clinical trial will provide early evidence on the efficacy of the VR-PAT for reducing self-reported pain and anxiety during outpatient laser procedures. The results from this trial will inform a large-scale, multisite study. Trial Registration: ClinicalTrials.gov: NCT05645224 [ https://clinicaltrials.gov/study/NCT05645224 ]

5 November 2025 in JMIR Preprints
Verified
Preprint
Open access
MAMegan Armstrong
Megan Armstrong
HWHannah Williams
Hannah Williams
EFEsteban Fernandez Faith
Esteban Fernandez Faith
ANAi Ni
Ai Ni
HXHenry Xiang
Henry Xiang
BACKGROUND Lasers have wide applications in medicine and dermatology, but are associated with pain and anxiety, particularly in younger patients. Pain mitigation is often limited to topical anesthetics in the outpatient setting. Distraction techniques are limited by the need for ocular protection, which can include adhesive eye patches that can completely occlude vision. Virtual reality is effective at managing procedural pain and anxiety under other short medical procedures and is a promising tool for this population. OBJECTIVE This trial aims to assess the safety, feasibility, and efficacy of Virtual Reality Pain Alleviation Therapeutic (VR-PAT) for pain management during outpatient laser procedures. METHODS 40 patients requiring outpatient laser therapy for at least two sessions will be recruited from a pediatric hospital in the Midwest for this crossover randomized, two-arm clinical trial with a 1:1 allocation ratio. During the first laser visit, the participant will be randomly assigned to either play the VR-PAT game during their procedure or wear the headset with a dark screen. Participants will answer questions about their pain, anxiety, and pain medication usage. Those playing the VR-PAT will additionally report simulator sickness symptoms and their experience playing the game. At their second laser visit, participants will crossover to the opposite intervention from the one they received at their first visit. The primary outcomes are the difference in self-reported pain and anxiety between the two interventions. RESULTS The study began enrollment in January 2023. To date, 44 participants have finished their first visit. Final results are planned for February 2026, after all data have been collected and analyzed. CONCLUSIONS Virtual reality is a promising digital technology that can improve the experience of patients requiring dermatologic laser therapy. Findings from this innovative randomized clinical trial will provide early evidence on the efficacy of the VR-PAT for reducing self-reported pain and anxiety during outpatient laser procedures. The results from this trial will inform a large-scale, multisite study. CLINICALTRIAL ClinicalTrials.gov: NCT05645224 [https://clinicaltrials.gov/study/NCT05645224]

9 June 2026 in JMIR Research Protocols
Verified
Journal Article
Open access
MAMegan Armstrong
Megan Armstrong
HWHannah Williams
Hannah Williams
EFEsteban Fernandez Faith
Esteban Fernandez Faith
ANAi Ni
Ai Ni
HXHenry Xiang
Henry Xiang
Background: Lasers have wide applications in medicine but are associated with pain and anxiety, particularly in younger patients. Pain mitigation is often limited to topical anesthetics in the outpatient setting. Distraction techniques are limited by the need for ocular protection, which can include eye patches that completely occlude vision. Virtual reality (VR) is effective at managing procedural pain and anxiety during other short medical procedures and is a promising tool for this population. Objective: This trial aims to assess the safety, feasibility, and efficacy of the virtual reality pain alleviation therapeutic (VR-PAT) for pain management during outpatient laser procedures. Methods: A total of 40 patients requiring outpatient laser therapy for at least 2 sessions will be recruited from a pediatric hospital in the Midwestern United States for this crossover randomized, 2-arm clinical trial. During the first laser visit, the participants will be randomly assigned to either play the VR-PAT game during their procedure or wear the headset with a dark screen. Participants will answer questions about their pain (Numeric Rating Scale 0‐10), anxiety (State-Trait Anxiety Inventory for Children, Numeric Rating Scale 0‐10, and Modified Yale Preoperative Anxiety Scale), and pain medication usage. Those playing the VR-PAT will report simulator sickness symptoms and their experience playing the game. At their second laser visit, participants will cross over to the opposite intervention. The primary outcomes are the differences in self-reported pain and anxiety between the 2 interventions. Feasibility outcomes include the proportion of screened patients who were eligible, have given consent, and completed both visits, as well as adverse events reported. To evaluate the efficacy of pain reduction, composite pain scores, and pain medication usage will be calculated for each laser visit. To evaluate the efficacy of anxiety reduction, the change in Modified Yale Preoperative Anxiety Scale scores will be compared between control and VR groups at each visit using the Wilcoxon rank sum tests. All statistical analyses will follow the intention-to-treat principle with regard to intervention assignment at each visit. Results: The study was funded in January 2023 and began enrollment at that time. A total of 44 participants were recruited, and data collection was completed in November 2025, with 40 participants completing both visits. The sample was balanced, with 40 participants using the intervention and participating in the control condition. The age range of the complete sample was 6 to 21 years at recruitment, and 22 (55%) were female. Data analysis is in progress with final results planned for June 2026. Conclusions: Findings from this innovative randomized clinical trial will provide early evidence on the efficacy of the VR-PAT in reducing self-reported pain and anxiety during outpatient laser procedures. The results from this trial will inform a large-scale, multisite study.